Vol. 6, Issue 8 (2017)

Author(s):
Dr. Mathew George, Dr. Lincy Joseph, Jeenu Joseph, Sharin Ann Abraham, Sruthy S, Nimitha Cheriyan and Madona Abraham

Abstract:

Chronic Kidney Disease (CKD) includes the continuum of kidney dysfunction from mild kidney damage to kidney failure. Ferric citrate is an iron-containing phosphate binder which decreases serum phosphate, increases haemoglobin and replete iron stores in patients with CKD. Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with CKD. Aim: To compare the effectiveness of ferric citrate versus sevelamer plus iron supplement in controlling hyperphosphatemia and iron deficiency anaemia in patients with chronic kidney disease. Materials and Method: A prospective study was conducted in Department of Nephrology at Pushpagiri Medical College Hospital. About 50 patients was recruited according to the inclusion and exclusion criteria, where 25 receiving ferric citrate (210mg ferric iron equivalent to 1g ferric citrate, twice daily) and 25 receiving sevelamer (400mg, thrice daily) plus iron supplement in stage 5 CKD patients on dialysis. Informed consent of the patients was taken by explaining the whole procedure. Serum phosphorus and TIBC was in consideration. The residual blood sample was collected from the biochemistry lab and the parameters were measured using semi auto analyzer. Then the effectiveness of the two drugs in controlling hyperphosphatemia and iron deficiency were studied. Result: Among the two drugs, ferric citrate had shown significant effect in reducing elevated phosphorus and TIBC level rather than sevelamer plus iron supplement.